Enterprise-safe use
Enterprise-safe by design. Company governance remains the authority.
PharmAI Pro teaches structured AI workflow use inside the boundaries that pharma teams already operate under: approved tools, data classification, source discipline, analytical validation, human review and formal company approval.
The programme helps teams prepare and challenge work. It does not approve it.
Public sessions
Public sessions use anonymised PharmAI Pro material.
- Synthetic or fully anonymised PharmAI Pro cases
- No participant company documents required
- No connection to live company databases or production systems
- No patient-level or patient-identifiable information
- No named individual HCP information — public sessions should not need it, and anything of that kind would have to be already permitted and properly anonymised
- No unpublished clinical data, regulated submissions or active regulatory materials
- No confidential net pricing, rebates, restricted commercial terms or production credentials
- No NDA-restricted competitive intelligence or content under legal hold
This list is illustrative, not a substitute for company policy. Participants remain responsible for following their employer's AI-use, data-classification, confidentiality and information-security rules.
Internal application
Internal application happens only inside the company's approved environment.
After a session, participants may apply the method internally only with inputs permitted by company policy and only inside company-approved tools and controls.
- 1Approved tool / tenant confirmed
- 2Permitted data classification and access confirmed
- 3Minimum necessary context prepared
- 4Sensitive details redacted or anonymised where required
- 5Structured output generated
- 6Evidence, logic, assumptions and risk validated
- 7Named human reviewer completes functional review
- 8Authoritative output saved in the approved repository
Tool-agnostic does not mean control-agnostic.
Examples only, and only where the company has approved them.
Microsoft CopilotChatGPT Enterprise / BusinessGemini EnterpriseClaude EnterpriseInternal company LLM platforms
- PharmAI Pro does not require a new platform.
- The availability of a named product does not itself establish approval for a given use.
- Data retention, model training, tenant, connector, browsing and repository controls depend on company configuration and contract.
- No universal claim is made that data never leaves an environment; that depends entirely on how the environment is configured.
- IT, security, privacy, legal and procurement controls remain company responsibilities.
AI assistance changes the workflow — not accountability.
Marketing
- Verify sources, evidence date and contradictions
- Distinguish evidence from assumption
- Pressure-test positioning and message logic
- Prepare agency and MLR handoffs
- Medical, Legal, Regulatory and MLR ownership and final approval remain unchanged
Insights & Analytics
- Validate source quality, grain, joins, filters, formulas and code
- Reconcile totals and test edge cases
- Document caveats, dependencies and limitations
- Forecast governance, model ownership, deployment controls and final recommendation accountability remain with the company
- Prototypes are not production assets until normal controls are complete
Market Access
Track in development
- Payer evidence, value-story, HTA and country-adaptation outputs require specialised access, medical, legal and local governance
- No standard paid curriculum is currently represented as available
Boundaries
Support the work. Do not bypass the controls.
PharmAI Pro helps teams
- Frame a task and prepare safe context
- Structure first drafts and analytical prototypes
- Surface evidence gaps, contradictions and assumptions
- Create QA checks, review questions and handoff registers
- Turn outputs into decision-ready narratives
- Build reusable workflow discipline
PharmAI Pro does not
- Replace Medical, Legal, Regulatory, MLR or final company approval
- Make medical, legal, regulatory, pricing, reimbursement or access decisions
- Replace source verification, analytical validation, forecast governance or model ownership
- Certify compliance or information security
- Replace IT architecture, security review, privacy assessment, vendor due diligence or procurement
- Deploy code, models or dashboards into production as part of standard training
- Take accountability for client decisions or outputs
Decision guide
Before using business context, ask seven questions.
- 1Is the AI tool and tenant approved for this use?
- 2Is the input classification permitted?
- 3Is this the minimum context necessary?
- 4Have restricted details been removed, redacted or anonymised where required?
- 5Are sources and dates identifiable?
- 6Is a named human reviewer accountable for evidence, logic and downstream use?
- 7Will the authoritative output be saved in the approved repository and formal review process?
If any answer is unclear, stop and follow company policy or seek the appropriate internal guidance before proceeding.
Need material for a manager, IT, compliance or procurement discussion?
PharmAI Pro can provide an Enterprise Reference explaining public-session boundaries, internal application principles, excluded data categories and the relationship with existing company review processes.
Supplier information
Participation terms
Formal quote